ACET Live signals | Maximize Profits with Getagraph.com

BUY 100484 min ago

@ $2.93

Issued: 14 Feb 2024 @ 15:42

Return: -33.33%

Previous signal: Feb 14 - 14:49

Previous signal: Sell

Return: -1.02 %

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 11:27):

Stats
Today's Volume	681 983
Average Volume	1.40M
Market Cap	160.23M
EPS	$-0.690 ( 2024-03-20 )
Next earnings date	( $-0.350 ) 2024-05-14
Last Dividend	$0.0100 ( 2018-09-21 )
Next Dividend	$0 ( N/A )
P/E	-0.590
ATR14	$0.00700 (0.36%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-25	Orbimed Advisors Llc	Buy	1 841 100	Common Stock
2024-01-25	Orbimed Advisors Llc	Buy	1 041 700	Common Stock
2024-01-25	Orbimed Advisors Llc	Buy	242 200	Common Stock
2024-01-25	Gordon Carl L	Buy	1 841 100	Common Stock
2024-01-25	Gordon Carl L	Buy	1 041 700	Common Stock

INSIDER POWER
58.23
Last 100 transactions
Buy: 13 014 935 \| Sell: 4 163 691

Volume Correlation

Long: 0.33 (neutral)

Short: -0.89 (strong negative)

Signal:(53.259) Neutral

Aceto Corporation Correlation

10 Most Positive Correlations
FGEN	0.968
ALLR	0.967
JBLU	0.965
RIDE	0.954
GSIT	0.953
TSVT	0.953
AIHS	0.952
ELEV	0.95
SEED	0.95
PPBT	0.95

10 Most Negative Correlations
HCKT	-0.963
XP	-0.961
NEOG	-0.96
VERA	-0.96
NCAC	-0.958
MSDA	-0.957
APEN	-0.957
BRIVU	-0.956
AGNCO	-0.955
MITA	-0.954

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Aceto Corporation Correlation - Currency/Commodity

0.56
( weak )

0.34
( neutral )

0.00
( neutral )

-0.59
( weak negative )

0.00
( neutral )

0.11
( neutral )

Aceto Corporation Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-6.10M (0.00 %)
EPS:	$-3.31

Q4	2023
Revenue:	$0
Gross Profit:	$-1.69M (0.00 %)
EPS:	$-0.690

Q3	2023
Revenue:	$0
Gross Profit:	$-2.35M (0.00 %)
EPS:	$-1.160

Q2	2023
Revenue:	$0
Gross Profit:	$-2.28M (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Aceto Corporation Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Aceto Corporation Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 0 - N/A | Divividend Growth Potential Score: 0 - N/A

Information

First Dividend	$0.100	2009-06-11
Last Dividend	$0.0100	2018-09-21
Next Dividend	$0	N/A
Payout Date	2018-10-09
Next Payout Date	N/A
# dividends	32	--
Total Paid Out	$2.12	--
Avg. Dividend % Per Year	0.00%	--
Score	1.82	--
Div. Sustainability Score	0
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-08-01)

$0 Estimate 0.00 %

Dividend Stability

0.11 Bad

Dividend Score

1.82

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2009	$0	0.00%
2010	$0	0.00%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0.0850	0.75%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

Unable to generate commentary due to missing data.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0	1.500	0	0	[0 - 0.5]
returnOnAssetsTTM	-0.682	1.200	-10.00	-10.00	[0 - 0.3]
returnOnEquityTTM	-1.689	1.500	-10.00	-10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	8.41	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	8.28	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	8.28	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.101	-1.500	8.32	-10.00	[0 - 0.6]
interestCoverageTTM	-6 335.00	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-2.18	2.00	-0.726	-1.452	[0 - 30]
freeCashFlowPerShareTTM	-2.28	2.00	-1.141	-2.28	[0 - 20]
debtEquityRatioTTM	0.123	-1.500	9.51	-10.00	[0 - 2.5]
grossProfitMarginTTM	0	1.000	-3.33	-3.33	[0.2 - 0.8]
operatingProfitMarginTTM	0	1.000	-2.00	-2.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-4.48	1.000	-10.00	-10.00	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				-0.673

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-0.639	1.000	-0.166	0	[1 - 100]
returnOnEquityTTM	-1.689	2.50	-10.00	-10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-2.28	2.00	-0.760	-2.28	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-2.18	2.00	-0.726	-1.452	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.0253	1.500	-3.50	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0	1.000	-2.50	0	[0.1 - 0.5]
Total Score				-2.09

Aceto Corporation

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.